Simulect Plus Standard Immunosuppression vs Standard Immunosuppression Alone in Lung Transplant Patients

Phase 3, randomised, double-blind trial in lung transplant rejection and Bronchiolitis Obliterans Syndrome (BOS) comparing basiliximab with placebo (2 arms). Primary endpoint: Proportion of patients who experience one or more acute allograft rejections in the first six months of treatment at 6 months. Started May 2004; status: completed.